Clinically, the decrease in glucose metabolism measured by the uptake of 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]-FDG), the radiolabeled glucose analog, with positron emission tomography (PET) analysis appears within days of initiating EGFR TKI therapy in NSCLC patients [21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.